10X Genomics is a biotechnology company offering a genomics platform supporting scientific research into life sciences such as oncology, immunology, and neuroscience that is headquartered in Pleasanton, California and was founded in 2012 by Ben Hindson and Serge Saxonov. 10X Genomics offers a platform which combines hardware, software and chemistry to perform single cel gene expression measurements, single cell immune profiling, single cell copy number variant detection, genome sequencing, exome sequencing, spatial gene expression analysis, single cell ATAC (Assay for Transposase Accessible Chromatin), and diploid de novo assembly to detect genetic variations.
On November 1, 2012 10X Genomics completed their seed funding round with $4.7 million in funding from Silicon Valley Bank.
On November 8, 2013 10X Genomics completed their series A funding round with $22. 4 million in funding from undisclosed investors.
On December 12, 2014 10X Genomics completed their series B funding round with $55.5 million in funding from Foresite Capital (lead investor), Venrock, and Paladin Capital Group.
On February 17, 2016 10X Genomics completed their series C funding round with $55 million in funding from Fidelity Management and Research Company (lead investor), Venrock, Softbank, Paladin Capital Group, and Foresite Capital. The company plans on using the funding to attempt to increase the sales of the companies GemCode and Chromium products.
On April 26, 2018 10X Genomics announced $50 million in series D funding from Meritech Capital Partners (lead investor), Wells Fargo Strategic Capital, Paladin Capital, Fidelity and the SoftBank Group. At the same time as announcing their series D funding the company also received a $75 debt facility with the Silicon Valley Bank.
On January 7, 2019 10X Genomics expanded their series D funding round with $35 million in funding from Meritech Capital (lead investor), Fidelity, and Wells Fargo.